In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 938-942

  Boos, M ^a   Mayer, S ^a   Fischer, A ^a   Kohrer K ^a   Scheuring, S ^a   Heisig, P ^a   Verhoef, J ^a   Fluit, A C ^a   Schmitz, F J ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0035112381     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.938-942.2001     Document Type: Article

References (44)

1. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux
2. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organisms
3. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
4. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
5. In vitro development of resistance to five quinolones and amoxicillin-clavunate in Streptococcus pneumoniae
6. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
7. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
8. DNA gyrase, topoisomerase IV and the 4-quinolones
9. Alterations in GyrA and ParC associate with fluoroquinolone resistance in Enterococcus faecium
10. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci
11. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
12. Primary targets of fluoroquinolones in Streptococcus pneumoniae
13. Identification of an efflux pump gene. pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
14. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus
15. Activity of the new fluoroquinolone trovafloxacin against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae
16. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance
17. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
18. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment
19. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different quinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
20. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
21. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus
22. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus
23. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis
24. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus
25. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine
26. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8796 clinical bacterial isolates
27. parC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
28. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA
29. Performance standards for antimicrobial susceptibility testing: 8th informational supplement
30. Natural functions of bacterial multidrug transporters
31. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance
32. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
33. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
34. DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones
35. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
36. In vitro selection of resistance to four β-lactams and azithromycin in Streptococcus pneumoniae
37. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
38. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus
39. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates
40. Characterization grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC
41. Hydrophilicity is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus
42. parC and gyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
43. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae